AWM Investment Company Inc. maintained its position in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 180,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Loxo Oncology makes up about 1.4% of AWM Investment Company Inc.’s holdings, making the stock its 23rd largest position. AWM Investment Company Inc. owned about 0.69% of Loxo Oncology worth $7,574,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc increased its stake in shares of Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 284 shares in the last quarter. BP PLC bought a new stake in shares of Loxo Oncology during the fourth quarter valued at approximately $245,000. American International Group Inc. increased its stake in shares of Loxo Oncology by 27.1% in the first quarter. American International Group Inc. now owns 9,749 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 2,081 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Loxo Oncology during the fourth quarter valued at about $352,000. Finally, Partners Group Holding AG acquired a new stake in shares of Loxo Oncology during the fourth quarter valued at about $382,000.
Loxo Oncology, Inc. (LOXO) traded down 1.66% on Monday, reaching $70.94. The company’s stock had a trading volume of 537,429 shares. The company’s market cap is $1.86 billion. The stock’s 50 day moving average price is $53.43 and its 200 day moving average price is $43.01. Loxo Oncology, Inc. has a 12 month low of $17.14 and a 12 month high of $79.00.
Loxo Oncology (NASDAQ:LOXO) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.20. Equities research analysts forecast that Loxo Oncology, Inc. will post ($4.22) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Loxo Oncology, Inc. (LOXO) Stake Maintained by AWM Investment Company Inc.” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://baseballnewssource.com/markets/loxo-oncology-inc-loxo-stake-maintained-by-awm-investment-company-inc-updated/985398.html.
A number of brokerages have recently commented on LOXO. Morgan Stanley reissued an “overweight” rating and set a $91.00 price objective on shares of Loxo Oncology in a report on Monday. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, June 8th. BTIG Research reiterated a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a research report on Tuesday, June 6th. Citigroup Inc. downgraded Loxo Oncology from a “buy” rating to a “neutral” rating and set a $45.00 target price for the company. in a research report on Friday, March 10th. Finally, Stifel Nicolaus lifted their price objective on Loxo Oncology from $52.00 to $71.00 and gave the company a “buy” rating in a research report on Monday, June 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $70.83.
In other Loxo Oncology news, Director Keith T. Flaherty sold 7,250 shares of the business’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $45.09, for a total value of $326,902.50. Following the completion of the sale, the director now directly owns 27,141 shares of the company’s stock, valued at $1,223,787.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.80% of the company’s stock.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with our FREE daily email newsletter.